Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8460277 | 0.82 | SRC (0.40) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| SCHEMBL15966852 | 0.78 | SRC (0.59) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL27956810 | 0.76 | CYP3A4 (0.50) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| SCHEMBL9874076 | 0.76 | SRC (0.50) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| SCHEMBL27332538 | 0.76 | SRC (0.61) | SRCL3MBTL1TDP1KDM4E | |
| Triphenyl Phosphate SCHEMBL1028391 | 0.75 | SRC (0.61) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| SCHEMBL3868422 | 0.74 | SRC (0.48) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| SCHEMBL8456528 | 0.72 | CA1 (0.61) | KDM4EMEN1KMT2ALMNANPSR1 | |
| SCHEMBL31156364 | 0.72 | SRC (0.47) | SRCL3MBTL1TDP1KDM4EMEN1 | |
| Triphenyl Phosphate SCHEMBL483692 | 0.72 | SRC (0.64) | SRCL3MBTL1TDP1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493747-B1 | PROCESS FOR PRODUCING MODIFIED PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2012-12-19 | — | — | EP | claimed |
| US-20050131208-A1 | Method for producing a modified peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-16 | — | — | US | claimed |
| EP-1493747-A1 | PROCESS FOR PRODUCING MODIFIED PEPTIDE | Daiichi Suntory Pharma Co., Ltd. (JP) | 2005-01-05 | — | — | EP | claimed |
| US-5717088-A | REACTING WITH A CYANOPHOSPHATE IN THE PRESENCE OF AN ALKALI METAL CYANIDE | SANKYO COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | claimed |
| EP-0004570-B1 | THIOL ESTERS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS FOR PREPARING CEPHALOSPORIN COMPOUNDS USING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-04-14 | — | — | EP | claimed |
| EP-0004570-A1 | Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1979-10-17 | — | — | EP | claimed |
| US-20260007733-A1 | Specific Saccharide Fragment for Development of Vibrio Cholerae Vaccines | UNIV JIANGNAN (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20250282810-A1 | Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides | JIANGNAN UNIVERSITY (CN) | 2025-09-11 | — | — | US | disclosed |
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | Asta Pharmaceuticals Co., Ltd. (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3147279-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | Fuji Chemical Industry Co., Ltd. (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | FUJI CHEMICAL INDUSTRIES CO., LTD. (JP) | 2017-03-23 | — | — | US | disclosed |
| US-20130204009-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-2615081-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0004570-B1 | THIOL ESTERS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS FOR PREPARING CEPHALOSPORIN COMPOUNDS USING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-04-14 | — | — | EP | disclosed |
| US-4314059-A | Process for preparing cephalosporin compounds | SHIBUYA CHISEI | 1982-02-02 | — | — | US | disclosed |
| US-4258195-A | Novel thiol esters and process for preparing cephalosporin compounds using same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | disclosed |
| EP-0004570-A1 | Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1979-10-17 | — | — | EP | disclosed |
| US-4138553-A | 3-Methylene cephalosporanic acid derivatives and process for preparation thereof | TEIJIN LIMITED (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282810-A1 | Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides | DDOST, OGA, DAD1 | SRC 633/4885L3MBTL1 2759/4885TDP1 4784/4885 |
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | NR2E3, NR3C2, NR5A1 | SRC 2231/4885L3MBTL1 4074/4885TDP1 4629/4885 |
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | NR2E3, NR3C2, NR5A1 | SRC 2231/4885L3MBTL1 4074/4885TDP1 4629/4885 |
| US-20260007733-A1 | Specific Saccharide Fragment for Development of Vibrio Cholerae Vaccines | STT3B, ST3GAL3, HACD3 | SRC 3539/4885L3MBTL1 183/4885TDP1 4655/4885 |
| US-20130204009-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | HPD, CYP2B6, PAH | SRC 2505/4885L3MBTL1 4404/4885TDP1 3117/4885 |
| US-20050131208-A1 | Method for producing a modified peptide | PTMS, DNPEP, QPCT | SRC 864/4885L3MBTL1 3023/4885TDP1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.